Tags

Type your tag names separated by a space and hit enter

Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
J Alzheimers Dis. 2011; 25(3):463-75.JA

Abstract

The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL19 total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 ± 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 ± 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL19 total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile.

Authors+Show Affiliations

Department of Neurology, University Medical Center, RWTH Aachen, Aachen, Germany. jschulz@ukaachen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21471647

Citation

Schulz, Jörg B., et al. "Sustained Effects of Once-daily Memantine Treatment On Cognition and Functional Communication Skills in Patients With Moderate to Severe Alzheimer's Disease: Results of a 16-week Open-label Trial." Journal of Alzheimer's Disease : JAD, vol. 25, no. 3, 2011, pp. 463-75.
Schulz JB, Rainer M, Klünemann HH, et al. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. J Alzheimers Dis. 2011;25(3):463-75.
Schulz, J. B., Rainer, M., Klünemann, H. H., Kurz, A., Wolf, S., Sternberg, K., & Tennigkeit, F. (2011). Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. Journal of Alzheimer's Disease : JAD, 25(3), 463-75. https://doi.org/10.3233/JAD-2011-101929
Schulz JB, et al. Sustained Effects of Once-daily Memantine Treatment On Cognition and Functional Communication Skills in Patients With Moderate to Severe Alzheimer's Disease: Results of a 16-week Open-label Trial. J Alzheimers Dis. 2011;25(3):463-75. PubMed PMID: 21471647.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. AU - Schulz,Jörg B, AU - Rainer,Michael, AU - Klünemann,Hans-Hermann, AU - Kurz,Alexander, AU - Wolf,Stefanie, AU - Sternberg,Kati, AU - Tennigkeit,Frank, PY - 2011/4/8/entrez PY - 2011/4/8/pubmed PY - 2011/11/16/medline SP - 463 EP - 75 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 25 IS - 3 N2 - The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL19 total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 ± 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 ± 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL19 total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/21471647/Sustained_effects_of_once_daily_memantine_treatment_on_cognition_and_functional_communication_skills_in_patients_with_moderate_to_severe_Alzheimer's_disease:_results_of_a_16_week_open_label_trial_ DB - PRIME DP - Unbound Medicine ER -